SPOTLIGHT: EMEA recommends Zeltia's Yondelis

The EMEA has recommended the European Commission approve Zeltia's drug Yondelis for the treatment of soft tissue sarcomas. The company's shares surged on the news. The recommendation comes almost four years after the EMEA rejected Zeltia's earlier submission. The company plans to begin selling the drug later this year. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.